China Osteoporosis Market Outlook to 2017- Traditional Chinese Medicine to Steer the Growth
The report titled “China Osteoporosis Market Outlook to 2017- Traditional Chinese Medicine to Steer the Growth” provides a comprehensive analysis of the various aspects such as market size, segmentation, trends and developments and future projections of the China Osteoporosis Market by number of diagnosed patients in the country, China Osteoporosis Drug Market with Teriparatide, Bisphosphonates, Traditional Chinese Medicine, Calcitonin, Strontium Ranelate and SERM as the key segments of the drug market. The report also discusses in detail the osteoporotic diagnostic services and equipments in China with DXA and QUS being the broad categories. Finally the report also gives a brief snapshot of the Hong Kong and Taiwan Osteoporosis markets. A detailed explanation of the various macro and industry factors which are driving the growth of this market in China has also been provided.
The number of osteoporotic patients in China has grown significantly in the recent past, primarily on account of the ageing population comprising of people 50 years and above. The incidence of the disease in the country has witnessed an increase of 300% in the last 30 years. Rise in the number of osteoporotic patients in the country has driven the growth of osteoporosis drug market in China. The overall drug market in China has been further segmented into Teriparatide, Bisphosphonates, Traditional Chinese Medicine, Calcitonin, Strontium Ranelate and SERM. It has grown at a CAGR of ~% during 2007-2012. The market for osteoporosis drugs in China reached around USD 1,608.9 million in 2012. The highest contributing segment to the overall drug market is teriparatide which had a share of close to around ~% in the year 2012. However the fastest growing segment in osteoporosis drug market is traditional Chinese medicine which is expected to grow at a CAGR of 9.7% during 2012-2017. Xianling Gubao which is the leading traditional Chinese medicine would contribute significantly towards the overall drugs market in China in the coming years. Increasing healthcare expenditure, rising personal disposable income and improving awareness among the urban population would drive the growth of the drugs market in the country.
The fragility fractures surgery in China arising out of osteoporotic patients is expected to reach USD ~ million in 2012 growing at CAGR of 7.0% during 2007-2012. This growth would be on account of growing number of hip fractures and vertebral fractures being reported in the country. For instance, the number of hip fractures in China is expected to reach 774,584 in the year 2017 while the number of vertebral fractures would grow to 2,013,919 in 2017. Rising number of osteoporotic patients, improving awareness and increasing availability of medical facilities would also drive the growth of diagnostic services market. The osteoporosis diagnosis services market is dominated by the DXA scans. The average cost of a DXA scan reached around USD 47.9 in 2012 while the number of diagnostic machines in China has reached 467 mark. The market for DXA scans has grown at a CAGR of 6.3% during 2007-2012. Likewise the market for QUS scan grew at a CAGR of 5.8% during 2007-2012 to register a market size of USD 20.2 million in 2012. The number of QUS machines in China has reached around 1,150 in 2012. In the coming years the overall market for osteoporosis diagnostic services is expected to grow at a CAGR of 5.1% during 2012-2017.
The report also explains in brief the Osteoporosis market in Hong Kong and China such as the incidences of fragility fractures, the average cost of treatment of hip, vertebral and wrist fractures and cost of diagnosis services as well. For instance the average annual cost of treatment of hip fracture in Hong Kong for the age group of 50-64 was around USD 11,389.2.
Key Topics covered in the report:
The number of osteoporotic patients in China has grown significantly in the recent past, primarily on account of the ageing population comprising of people 50 years and above. The incidence of the disease in the country has witnessed an increase of 300% in the last 30 years. Rise in the number of osteoporotic patients in the country has driven the growth of osteoporosis drug market in China. The overall drug market in China has been further segmented into Teriparatide, Bisphosphonates, Traditional Chinese Medicine, Calcitonin, Strontium Ranelate and SERM. It has grown at a CAGR of ~% during 2007-2012. The market for osteoporosis drugs in China reached around USD 1,608.9 million in 2012. The highest contributing segment to the overall drug market is teriparatide which had a share of close to around ~% in the year 2012. However the fastest growing segment in osteoporosis drug market is traditional Chinese medicine which is expected to grow at a CAGR of 9.7% during 2012-2017. Xianling Gubao which is the leading traditional Chinese medicine would contribute significantly towards the overall drugs market in China in the coming years. Increasing healthcare expenditure, rising personal disposable income and improving awareness among the urban population would drive the growth of the drugs market in the country.
The fragility fractures surgery in China arising out of osteoporotic patients is expected to reach USD ~ million in 2012 growing at CAGR of 7.0% during 2007-2012. This growth would be on account of growing number of hip fractures and vertebral fractures being reported in the country. For instance, the number of hip fractures in China is expected to reach 774,584 in the year 2017 while the number of vertebral fractures would grow to 2,013,919 in 2017. Rising number of osteoporotic patients, improving awareness and increasing availability of medical facilities would also drive the growth of diagnostic services market. The osteoporosis diagnosis services market is dominated by the DXA scans. The average cost of a DXA scan reached around USD 47.9 in 2012 while the number of diagnostic machines in China has reached 467 mark. The market for DXA scans has grown at a CAGR of 6.3% during 2007-2012. Likewise the market for QUS scan grew at a CAGR of 5.8% during 2007-2012 to register a market size of USD 20.2 million in 2012. The number of QUS machines in China has reached around 1,150 in 2012. In the coming years the overall market for osteoporosis diagnostic services is expected to grow at a CAGR of 5.1% during 2012-2017.
The report also explains in brief the Osteoporosis market in Hong Kong and China such as the incidences of fragility fractures, the average cost of treatment of hip, vertebral and wrist fractures and cost of diagnosis services as well. For instance the average annual cost of treatment of hip fracture in Hong Kong for the age group of 50-64 was around USD 11,389.2.
Key Topics covered in the report:
- The market size of China Osteoporosis Market by number of osteoporosis patients diagnosed in the country.
- The market size of China Osteoporosis Drugs Market on the basis of revenue.
- The market segmentation of China Osteoporosis Drug Market by Teriparatide, Bisphosphonate, Traditional Chinese Medicine, Calcitonin, Strontium Ranelate and SERM.
- The market size and future outlook and projection for Teriparatide, Bisphosphonates, Traditional Chinese Medicine, Calcitonin, Strontium Ranelate and SERM on the basis of revenue.
- The future outlook and projections for China Osteoporosis Drug Market on the basis of revenue.
- Market share of major osteoporosis drug companies on the basis of revenue.
- The market size of China Fracture Surgery Market on the basis of revenue.
- The market segmentation China Fracture surgery market by vertebral fracture surgery and hip fracture surgery.
- The market size and future outlook and projections of vertebral fracture surgery market and hip fracture surgery market.
- The market size of China Osteoporosis Diagnostic services market.
- The market segmentation of China Osteoporosis Diagnostic services market by DXA scans and QUS scans.
- The market size and future outlook and projections for DXA scans and QUS scan market on the basis of revenue.
- The market size of China Diagnosis Equipment Market.
- The market segmentation of China Diagnosis Equipment Market by DXA machines and QUS machines
- The market size and future outlook and projections of DXA machines and QUS machines on the basis of revenue.
- Snapshots of Hong Kong and Taiwan Osteoporosis Market.
1. CHINA OSTEOPOROSIS MARKET INTRODUCTION
2. CHINA OSTEOPOROSIS MARKET SIZE BY NUMBER OF PEOPLE SUFFERING FROM OSTEOPOROSIS, 2007-2012
3. CHINA OSTEOPOROSIS DRUG MARKET SIZE AND INTRODUCTION, 2007-2012
4. CHINA OSTEOPOROSIS DRUG MARKET SEGMENTATION, 2007-2012
4.1. China Teriparatide Drug Market Size and Introduction, 2007-2012
4.2. China Teriparatide Drug Market Future Outlook and Projections, 2013-2017
4.3. China Bisphosphonates Drug Market Size and Introduction, 2007-2012
4.4. China Bisphosphonates Drug Market Future Outlook and Projections, 2013-2017
4.5. China Traditional Chinese Medicine Market Size and Introduction, 2007-2012
4.6. China Traditional Chinese Medicine Market Future Outlook and Projections, 2013-2017
4.7. China Calcitonin Drug Market Size and Introduction, 2007-2012
4.8. China Calcitonin Drug Market Future Outlook and Projections, 2013-2017
4.9. China Strontium Ranelate Drug Market Size and Introduction, 2007-2012
4.10. China Strontium Ranelate Drug Market Future Outlook and Projections, 2013-2017
4.11. China SERM Drug Market Size and Introduction, 2007-2012
4.12. China SERM Drug Market Future Outlook and Projections, 2013-2017
5. MARKET SHARE OF MAJOR PLAYERS IN THE CHINA OSTEOPOROSIS DRUGS MARKET, 2012
6. COMPANY PROFILES OF MAJOR PLAYERS IN THE CHINA OSTEOPOROSIS DRUGS MARKET
6.1. Novartis
Company Overview
Financial Performance
Business Strategies
6.2. Eli Lilly and Company
Company Overview
Financial Performance
Business Strategies
6.3. Merck
Company Overview
Financial Performance
Business Strategies
6.4. Tongjitang Chinese Medicines Co- TCM
Company Overview
Financial Performance
Business Strategy
7. CHINA OSTEOPOROSIS DRUGS MARKET FUTURE OUTLOOK AND PROJECTIONS, 2013-2017
8. CHINA OSTEOPOROSIS FRACTURE SURGERY MARKET SIZE AND INTRODUCTION, 2007-2012
9. CHINA OSTEOPOROSIS FRACTURE SURGERY MARKET SEGMENTATION, 2007-2012
9.1. China Vertebral Fracture Surgery Market Introduction and Size, 2007-2012
9.2. China Vertebral Fracture Surgery Market Future Outlook and Projections, 2013-2017
9.3. China Hip Fracture Surgery Market Size and Introduction, 2007-2012
9.4. China Hip Fracture Surgery Market Future Outlook and Projections, 2013-2017
10. CHINA OSTEOPOROSIS FRACTURE SURGERY MARKET FUTURE OUTLOOK AND PROJECTIONS, 2013-2017
11. CHINA OSTEOPOROSIS DIAGNOSTIC SERVICES MARKET SIZE AND INTRODUCTION, 2006-2012
12. CHINA OSTEOPOROSIS DIAGNOSTIC SERVICES MARKET SEGMENTATION, 2007-2012
12.1. China DXA Scans Market Size and Introduction, 2007-2012
12.2. China DXA Scans Future Outlook and Projections, 2013-2017
12.3. China QUS Market Size and Introduction, 2007-2012
12.4. China QUS Scans Market Future Outlook and Projections, 2013-2017
13. CHINA OSTEOPOROSIS DIAGNOSTIC SERVICES MARKET FUTURE OUTLOOK AND PROJECTIONS, 2013-2017
14. CHINA OSTEOPOROSIS DIAGNOSIS EQUIPMENT MARKET
14.1. DXA Equipment Market
14.2. Qus Equipment Market
15. CHINA OSTEOPOROSIS MARKET TRENDS AND DEVELOPMENTS
Low Calcium Intake
Complex procedures replaced by Minimal Invasive Surgery
Generic Drugs Replacing the Patented Drugs
Government Health care Initiatives
16. CHINA OSTEOPOROSIS MARKET FUTURE OUTLOOK AND PROJECTIONS, 2013-2017
16.1. Cause and Effect Relationship between Dependent and Independent Factors Prevailing in the China Osteoporosis Market
17. CHINA OSTEOPOROSIS MARKET GOVERNMENT POLICIES AND INITIATIVES
18. HONG KONG OSTEOPOROSIS MARKET
19. TAIWAN OSTEOPOROSIS MARKET
20. MACRO ECONOMIC INDICATORS FOR CHINA OSTEOPOROSIS MARKET, 2007-2017
20.1. Rising Ageing Population, 2007-2017
20.2. Rising Healthcare Expenditure, 2007-2017
20.3. Increasing Household Consumption Expenditure, 2007-2017
20.4. Health Insurance Premium, 2007-2017
21. APPENDIX
21.1. Market Definitions
21.2. Abbreviations
21.3. Research Methodology
Data Collection Methods
Approach
Variables (Dependent and Independent)
Multi Factor Based Sensitivity Model
Final Conclusion
21.4. Disclaimer
2. CHINA OSTEOPOROSIS MARKET SIZE BY NUMBER OF PEOPLE SUFFERING FROM OSTEOPOROSIS, 2007-2012
3. CHINA OSTEOPOROSIS DRUG MARKET SIZE AND INTRODUCTION, 2007-2012
4. CHINA OSTEOPOROSIS DRUG MARKET SEGMENTATION, 2007-2012
4.1. China Teriparatide Drug Market Size and Introduction, 2007-2012
4.2. China Teriparatide Drug Market Future Outlook and Projections, 2013-2017
4.3. China Bisphosphonates Drug Market Size and Introduction, 2007-2012
4.4. China Bisphosphonates Drug Market Future Outlook and Projections, 2013-2017
4.5. China Traditional Chinese Medicine Market Size and Introduction, 2007-2012
4.6. China Traditional Chinese Medicine Market Future Outlook and Projections, 2013-2017
4.7. China Calcitonin Drug Market Size and Introduction, 2007-2012
4.8. China Calcitonin Drug Market Future Outlook and Projections, 2013-2017
4.9. China Strontium Ranelate Drug Market Size and Introduction, 2007-2012
4.10. China Strontium Ranelate Drug Market Future Outlook and Projections, 2013-2017
4.11. China SERM Drug Market Size and Introduction, 2007-2012
4.12. China SERM Drug Market Future Outlook and Projections, 2013-2017
5. MARKET SHARE OF MAJOR PLAYERS IN THE CHINA OSTEOPOROSIS DRUGS MARKET, 2012
6. COMPANY PROFILES OF MAJOR PLAYERS IN THE CHINA OSTEOPOROSIS DRUGS MARKET
6.1. Novartis
Company Overview
Financial Performance
Business Strategies
6.2. Eli Lilly and Company
Company Overview
Financial Performance
Business Strategies
6.3. Merck
Company Overview
Financial Performance
Business Strategies
6.4. Tongjitang Chinese Medicines Co- TCM
Company Overview
Financial Performance
Business Strategy
7. CHINA OSTEOPOROSIS DRUGS MARKET FUTURE OUTLOOK AND PROJECTIONS, 2013-2017
8. CHINA OSTEOPOROSIS FRACTURE SURGERY MARKET SIZE AND INTRODUCTION, 2007-2012
9. CHINA OSTEOPOROSIS FRACTURE SURGERY MARKET SEGMENTATION, 2007-2012
9.1. China Vertebral Fracture Surgery Market Introduction and Size, 2007-2012
9.2. China Vertebral Fracture Surgery Market Future Outlook and Projections, 2013-2017
9.3. China Hip Fracture Surgery Market Size and Introduction, 2007-2012
9.4. China Hip Fracture Surgery Market Future Outlook and Projections, 2013-2017
10. CHINA OSTEOPOROSIS FRACTURE SURGERY MARKET FUTURE OUTLOOK AND PROJECTIONS, 2013-2017
11. CHINA OSTEOPOROSIS DIAGNOSTIC SERVICES MARKET SIZE AND INTRODUCTION, 2006-2012
12. CHINA OSTEOPOROSIS DIAGNOSTIC SERVICES MARKET SEGMENTATION, 2007-2012
12.1. China DXA Scans Market Size and Introduction, 2007-2012
12.2. China DXA Scans Future Outlook and Projections, 2013-2017
12.3. China QUS Market Size and Introduction, 2007-2012
12.4. China QUS Scans Market Future Outlook and Projections, 2013-2017
13. CHINA OSTEOPOROSIS DIAGNOSTIC SERVICES MARKET FUTURE OUTLOOK AND PROJECTIONS, 2013-2017
14. CHINA OSTEOPOROSIS DIAGNOSIS EQUIPMENT MARKET
14.1. DXA Equipment Market
14.2. Qus Equipment Market
15. CHINA OSTEOPOROSIS MARKET TRENDS AND DEVELOPMENTS
Low Calcium Intake
Complex procedures replaced by Minimal Invasive Surgery
Generic Drugs Replacing the Patented Drugs
Government Health care Initiatives
16. CHINA OSTEOPOROSIS MARKET FUTURE OUTLOOK AND PROJECTIONS, 2013-2017
16.1. Cause and Effect Relationship between Dependent and Independent Factors Prevailing in the China Osteoporosis Market
17. CHINA OSTEOPOROSIS MARKET GOVERNMENT POLICIES AND INITIATIVES
18. HONG KONG OSTEOPOROSIS MARKET
19. TAIWAN OSTEOPOROSIS MARKET
20. MACRO ECONOMIC INDICATORS FOR CHINA OSTEOPOROSIS MARKET, 2007-2017
20.1. Rising Ageing Population, 2007-2017
20.2. Rising Healthcare Expenditure, 2007-2017
20.3. Increasing Household Consumption Expenditure, 2007-2017
20.4. Health Insurance Premium, 2007-2017
21. APPENDIX
21.1. Market Definitions
21.2. Abbreviations
21.3. Research Methodology
Data Collection Methods
Approach
Variables (Dependent and Independent)
Multi Factor Based Sensitivity Model
Final Conclusion
21.4. Disclaimer
LIST OF FIGURES
Figure 1: China Osteoporosis Market Size by Population Suffering From Osteoporosis in Million, 2007-2012
Figure 2: China Osteoporosis Drug Market Size on the Basis of Revenue in USD Million, 2007-2012
Figure 3: China Teriparatide Drug Market Size on the Basis of Revenue in USD Million, 2007-2012
Figure 4: China Teriparatide Drug Market Future Projections on the Basis of Revenue in USD Million, 2013-2017
Figure 5: China Bisphosphonate Drug Market Size on the Basis of Revenue in USD Million, 2007-2012
Figure 6: China Bisphosphonate Drug Future Projections on the Basis of Revenue in USD Million, 2013-2017
Figure 7: China Traditional Chinese Medicine Drug Market Size on the Basis of Revenue in USD Million, 2007-2012
Figure 8: China Traditional Chinese Drug Future Projections on the Basis of Revenue in USD Million, 2013-2017
Figure 9 : China Calcitonin Drug Market Size on the Basis of Revenue in USD Million, 2007-2012
Figure 10: China Calcitonin Drug Future Projections on the Basis of Revenue in USD Million, 2013-2017
Figure 11: China Strontium Ranelate Drug Market Size on the Basis of Revenue in USD Million, 2007-2012
Figure 12: China Strontium Ranelate Drug Future Projections on the Basis of Revenue in USD Million, 2013-2017
Figure 13: China SERM (Raloxifene) Drug Market Size Projections on the Basis of Revenue in USD Million, 2013-2017
Figure 14: China SERM (Raloxifene) Drug Future Projections on the Basis of Revenue in USD Million, 2013-2017
Figure 15: Market Share of Major Players in China Osteoporosis Drugs Market, 2012
Figure 16: Novartis Associates by Region, 2012
Figure 17: Novartis Sales Revenue in USD Million, 2010-2012
Figure 18: Eli Lilly and Company Sales Revenue in USD Million, 2007-2012
Figure 19: Merck Sales Revenue in USD Million, 2007-2012
Figure 20: Tongjitang (Xianling Gubao) Sales Revenue in USD Million, 2006-2008
Figure 21: China Osteoporosis Drug Market Future Projections on the Basis of Revenue in USD Million, 2013-2017
Figure 22: China Fracture Surgery Market Size on the Basis of Revenue in USD Million, 2007-2012
Figure 23: China Fracture Surgery Market Segmentation by Vertebral Fractures and Hip Fractures on the Basis of Revenue in Percentage (%), 2007-2012
Figure 24: China Vertebral Fracture Surgery Market Size on the Basis of Revenue in USD Million, 2007-2012
Figure 25: China Vertebral Fracture Surgery Market Future Projections on the Basis of Expenditure on Hip Fracture Surgeries in USD Million, 2013-2017
Figure 26: China Hip Fracture Surgery Market Size on the Basis of Revenue in USD Million, 2007-2012
Figure 27: China Hip Fracture Surgery Market Future Projections on the Basis of Revenue in USD Million, 2013-2017
Figure 28: China Fracture Surgery Market Future Projections on the Basis of Revenue in USD Million, 2013-2017
Figure 29: Osteoporosis Self Assessment Tool for Asians
Figure 30: China Diagnostic Services Market Size on the Basis of Expenditure on Hip Fracture Surgeries in USD Million, 2007-2012
Figure 31: China Diagnostic Services Market Segmentation by DXA Scans and QUS Scans on the Basis of Revenue in Percentage (%), 2007-2012
Figure 32: China DXA Scans Market Size on the Basis of Expenditure on DXA Scans in USD Million, 2007-2012
Figure 33: China DXA Scans Market Future Projections on the Basis of Expenditure on DXA Scans in USD Million, 2013-2017
Figure 34: China QUS Scans Market Size on the Basis of Revenue in USD Million, 2007-2012
Figure 35: China QUS Scans Market Future Projections on the Basis of Expenditure on QUS Scans in USD Million, 2013-2017
Figure 36: China Diagnostic Services Market Future Projections on the Basis of Revenue in USD Million, 2013-2017
Figure 37: China Osteoporosis Market Future Projections on the Basis Population Suffering from Osteoporosis in Million, 2013-2017
Figure 38: China Ageing (50 years and above) Population in Million, 2007-2017
Figure 39: China Health Care Expenditure in USD Million, 2007-2017
Figure 40: China Rising Household Final Consumption Expenditure in USD Million, 2007-2017
Figure 41: China Health Insurance Premium in USD Million, 2007-2017
Figure 1: China Osteoporosis Market Size by Population Suffering From Osteoporosis in Million, 2007-2012
Figure 2: China Osteoporosis Drug Market Size on the Basis of Revenue in USD Million, 2007-2012
Figure 3: China Teriparatide Drug Market Size on the Basis of Revenue in USD Million, 2007-2012
Figure 4: China Teriparatide Drug Market Future Projections on the Basis of Revenue in USD Million, 2013-2017
Figure 5: China Bisphosphonate Drug Market Size on the Basis of Revenue in USD Million, 2007-2012
Figure 6: China Bisphosphonate Drug Future Projections on the Basis of Revenue in USD Million, 2013-2017
Figure 7: China Traditional Chinese Medicine Drug Market Size on the Basis of Revenue in USD Million, 2007-2012
Figure 8: China Traditional Chinese Drug Future Projections on the Basis of Revenue in USD Million, 2013-2017
Figure 9 : China Calcitonin Drug Market Size on the Basis of Revenue in USD Million, 2007-2012
Figure 10: China Calcitonin Drug Future Projections on the Basis of Revenue in USD Million, 2013-2017
Figure 11: China Strontium Ranelate Drug Market Size on the Basis of Revenue in USD Million, 2007-2012
Figure 12: China Strontium Ranelate Drug Future Projections on the Basis of Revenue in USD Million, 2013-2017
Figure 13: China SERM (Raloxifene) Drug Market Size Projections on the Basis of Revenue in USD Million, 2013-2017
Figure 14: China SERM (Raloxifene) Drug Future Projections on the Basis of Revenue in USD Million, 2013-2017
Figure 15: Market Share of Major Players in China Osteoporosis Drugs Market, 2012
Figure 16: Novartis Associates by Region, 2012
Figure 17: Novartis Sales Revenue in USD Million, 2010-2012
Figure 18: Eli Lilly and Company Sales Revenue in USD Million, 2007-2012
Figure 19: Merck Sales Revenue in USD Million, 2007-2012
Figure 20: Tongjitang (Xianling Gubao) Sales Revenue in USD Million, 2006-2008
Figure 21: China Osteoporosis Drug Market Future Projections on the Basis of Revenue in USD Million, 2013-2017
Figure 22: China Fracture Surgery Market Size on the Basis of Revenue in USD Million, 2007-2012
Figure 23: China Fracture Surgery Market Segmentation by Vertebral Fractures and Hip Fractures on the Basis of Revenue in Percentage (%), 2007-2012
Figure 24: China Vertebral Fracture Surgery Market Size on the Basis of Revenue in USD Million, 2007-2012
Figure 25: China Vertebral Fracture Surgery Market Future Projections on the Basis of Expenditure on Hip Fracture Surgeries in USD Million, 2013-2017
Figure 26: China Hip Fracture Surgery Market Size on the Basis of Revenue in USD Million, 2007-2012
Figure 27: China Hip Fracture Surgery Market Future Projections on the Basis of Revenue in USD Million, 2013-2017
Figure 28: China Fracture Surgery Market Future Projections on the Basis of Revenue in USD Million, 2013-2017
Figure 29: Osteoporosis Self Assessment Tool for Asians
Figure 30: China Diagnostic Services Market Size on the Basis of Expenditure on Hip Fracture Surgeries in USD Million, 2007-2012
Figure 31: China Diagnostic Services Market Segmentation by DXA Scans and QUS Scans on the Basis of Revenue in Percentage (%), 2007-2012
Figure 32: China DXA Scans Market Size on the Basis of Expenditure on DXA Scans in USD Million, 2007-2012
Figure 33: China DXA Scans Market Future Projections on the Basis of Expenditure on DXA Scans in USD Million, 2013-2017
Figure 34: China QUS Scans Market Size on the Basis of Revenue in USD Million, 2007-2012
Figure 35: China QUS Scans Market Future Projections on the Basis of Expenditure on QUS Scans in USD Million, 2013-2017
Figure 36: China Diagnostic Services Market Future Projections on the Basis of Revenue in USD Million, 2013-2017
Figure 37: China Osteoporosis Market Future Projections on the Basis Population Suffering from Osteoporosis in Million, 2013-2017
Figure 38: China Ageing (50 years and above) Population in Million, 2007-2017
Figure 39: China Health Care Expenditure in USD Million, 2007-2017
Figure 40: China Rising Household Final Consumption Expenditure in USD Million, 2007-2017
Figure 41: China Health Insurance Premium in USD Million, 2007-2017
LIST OF TABLES
Table 1: World Health Organization Criteria for Osteoporosis
Table 2: China Osteoporosis Drug Market Segmentation by Teriparatide, Bisphosphonate, Traditional Chinese Medicine, Calcitonin, Strontium Ranelate and SERM on the Basis of Revenue in Percentage (%) Million, 2007-2012
Table 3: China Teriparatide Drug Market Size on the Basis of Revenue in USD Million, 2007-2012
Table 4: China Teriparatide Drug Market Future Projections on the Basis of Revenue in USD Million, 2013-2017
Table 5: China Alendronate Drug Market Size on the Basis of Revenue in USD Million, 2007-2012
Table 6: China Zoledronic Acid Drug Market Size on the Basis of Revenue in USD Million, 2007-2012
Table 7: China Alendronate Drug Future Projections on the Basis of Revenue in USD Million, 2013-2017
Table 8: China Zoledronic Acid Drug Future Projections on the Basis of Revenue in USD Million, 2013-2017
Table 9: China Xianling Gubao Number of Formulary Hospitals, 2006-2008
Table 10: China Xianling Gubao Formulary Class 3 Hospitals as Percentage of Total Class 3 Hospitals, 2006-2008
Table 11: Number of Xianling Gubao Stocking Retail Pharmacies and Xianling Gubao Stocking Retail Authorized Pharmacies under the National Medical Insurance Program in China in Units, 2006-2008
Table 12: China Traditional Chinese Medicine (Xianling Gubao) Market Size on the Basis of Revenue in USD Million, 2007-2012
Table 13: China Traditional Chinese Medicine Future Projections on the Basis of Revenue in USD Million, 2013-2017
Table 14: China Calcitonin Drug Market Size on the Basis of Revenue in USD Million, 2013-2017
Table 15: China Calcitonin Drug Future Projections on the Basis of Revenue in USD Million, 2013-2017
Table 16: China Strontium Ranelate Drug Market Size on the Basis of Revenue in USD Million, 2013-2017
Table 17: China Strontium Ranelate Drug Future Projections on the Basis of Revenue in USD Million, 2013-2017
Table 18: China SERM (Raloxifene) Market Size on the Basis of Revenue in USD Million, 2007-2012
Table 19: China SERM (Raloxifene) Drug Future Projections on the Basis of Revenue in USD Million, 2013-2017
Table 20: List of Therapeutic Areas of Novartis
Table 21: Eli Lilly and Company Sales Revenue in USD Million, 2007-2012
Table 22: China Vertebral Fracture Incidences in Units, 2007-2012
Table 23: China Hip Fracture Incidences in Units and Estimated Hip Fracture Direct Cost in USD, 2007-2012
Table 24: China Hip Fracture Treatment Cost Comparison with Other Major Diseases in USD, 2007
Table 25: China Hip Fracture Incidences (Per 100,000) Among Men and Women Compared with Other Major Countries
Table 26: Number of Available DXA Machines in Various Asian Countries in Units, 2008
Table 27: China DXA Equipment Market Size by Number of Machines in Units, 2008 and 2012
Table 28: Recommendations for BMD Testing by DXA following QUS Test
Table 29: China QUS Equipment Market Size by Number of Machines in Units, 2008 and 2012
Table 30: China Bone Densitometry Machine Suppliers
Table 31: Cause and Effect Relationship Analysis between Industry Factors and Expected Industry Prospects of China Osteoporosis Market
Table 33: Hong Kong Incidence Rate of Hip Fractures (per 100,000 population), 1966, 1985, 2001 and 2006
Table 34: Hong Kong Age Specific Fracture (Per 100,000) for Women, 2004
Table 35: Hong Kong Mean Annual Cost of Fracture and Treatment per Patient in USD, 2009
Table 36: One Way Sensitivity Analysis of Different Drugs in Women Aged 70 years in USD, 2009
Table 37: Taiwan Hip Fracture and Treatment Cost in USD Million, 2006
Table 38: Taiwan DXA and QUS Machine Penetration in Units (Per 10000 population) and Scan Cost (In USD), 2006
Table 39: Correlation Matrix for China Osteoporosis Market
Table 40: Regression Coefficients Output
Table 1: World Health Organization Criteria for Osteoporosis
Table 2: China Osteoporosis Drug Market Segmentation by Teriparatide, Bisphosphonate, Traditional Chinese Medicine, Calcitonin, Strontium Ranelate and SERM on the Basis of Revenue in Percentage (%) Million, 2007-2012
Table 3: China Teriparatide Drug Market Size on the Basis of Revenue in USD Million, 2007-2012
Table 4: China Teriparatide Drug Market Future Projections on the Basis of Revenue in USD Million, 2013-2017
Table 5: China Alendronate Drug Market Size on the Basis of Revenue in USD Million, 2007-2012
Table 6: China Zoledronic Acid Drug Market Size on the Basis of Revenue in USD Million, 2007-2012
Table 7: China Alendronate Drug Future Projections on the Basis of Revenue in USD Million, 2013-2017
Table 8: China Zoledronic Acid Drug Future Projections on the Basis of Revenue in USD Million, 2013-2017
Table 9: China Xianling Gubao Number of Formulary Hospitals, 2006-2008
Table 10: China Xianling Gubao Formulary Class 3 Hospitals as Percentage of Total Class 3 Hospitals, 2006-2008
Table 11: Number of Xianling Gubao Stocking Retail Pharmacies and Xianling Gubao Stocking Retail Authorized Pharmacies under the National Medical Insurance Program in China in Units, 2006-2008
Table 12: China Traditional Chinese Medicine (Xianling Gubao) Market Size on the Basis of Revenue in USD Million, 2007-2012
Table 13: China Traditional Chinese Medicine Future Projections on the Basis of Revenue in USD Million, 2013-2017
Table 14: China Calcitonin Drug Market Size on the Basis of Revenue in USD Million, 2013-2017
Table 15: China Calcitonin Drug Future Projections on the Basis of Revenue in USD Million, 2013-2017
Table 16: China Strontium Ranelate Drug Market Size on the Basis of Revenue in USD Million, 2013-2017
Table 17: China Strontium Ranelate Drug Future Projections on the Basis of Revenue in USD Million, 2013-2017
Table 18: China SERM (Raloxifene) Market Size on the Basis of Revenue in USD Million, 2007-2012
Table 19: China SERM (Raloxifene) Drug Future Projections on the Basis of Revenue in USD Million, 2013-2017
Table 20: List of Therapeutic Areas of Novartis
Table 21: Eli Lilly and Company Sales Revenue in USD Million, 2007-2012
Table 22: China Vertebral Fracture Incidences in Units, 2007-2012
Table 23: China Hip Fracture Incidences in Units and Estimated Hip Fracture Direct Cost in USD, 2007-2012
Table 24: China Hip Fracture Treatment Cost Comparison with Other Major Diseases in USD, 2007
Table 25: China Hip Fracture Incidences (Per 100,000) Among Men and Women Compared with Other Major Countries
Table 26: Number of Available DXA Machines in Various Asian Countries in Units, 2008
Table 27: China DXA Equipment Market Size by Number of Machines in Units, 2008 and 2012
Table 28: Recommendations for BMD Testing by DXA following QUS Test
Table 29: China QUS Equipment Market Size by Number of Machines in Units, 2008 and 2012
Table 30: China Bone Densitometry Machine Suppliers
Table 31: Cause and Effect Relationship Analysis between Industry Factors and Expected Industry Prospects of China Osteoporosis Market
Table 33: Hong Kong Incidence Rate of Hip Fractures (per 100,000 population), 1966, 1985, 2001 and 2006
Table 34: Hong Kong Age Specific Fracture (Per 100,000) for Women, 2004
Table 35: Hong Kong Mean Annual Cost of Fracture and Treatment per Patient in USD, 2009
Table 36: One Way Sensitivity Analysis of Different Drugs in Women Aged 70 years in USD, 2009
Table 37: Taiwan Hip Fracture and Treatment Cost in USD Million, 2006
Table 38: Taiwan DXA and QUS Machine Penetration in Units (Per 10000 population) and Scan Cost (In USD), 2006
Table 39: Correlation Matrix for China Osteoporosis Market
Table 40: Regression Coefficients Output
